How long you can live with melanoma depends almost entirely on when it’s caught. Melanoma found before it spreads beyond the skin has a 5-year survival rate of 100%, while melanoma that has reached distant organs drops to 34%. But even that number is changing fast: newer treatments now help roughly half of patients with advanced melanoma live 10 years or longer.
Survival Rates by Stage
Melanoma survival is tracked using three broad categories based on how far the cancer has spread. Federal cancer data from 2016 to 2022 shows these 5-year relative survival rates:
- Localized (still in the skin): 100%
- Regional (spread to nearby lymph nodes): 76%
- Distant (spread to other organs): 34%
Stage 0 melanoma, where abnormal cells are only in the top layer of skin, has a 5- and 10-year survival rate of 99% to 100% after surgical removal. At this stage, the melanoma has essentially no ability to threaten your life if it’s fully removed.
These numbers are population averages. They include people diagnosed years ago who didn’t have access to today’s treatments. For someone diagnosed now, the outlook is generally better than these statistics suggest, especially for advanced disease.
How Tumor Thickness Affects Outlook
Beyond stage, the single most important measurement is how deep the melanoma has grown into the skin, measured in millimeters. Thinner melanomas have dramatically better outcomes:
- Less than 1 mm: 95% to 100% five-year survival
- 1 to 2 mm: 80% to 96%
- 2.1 to 4 mm: 60% to 75%
- Greater than 4 mm: 37% to 50%
This is why early detection matters so much. A melanoma caught at less than a millimeter thick is almost always curable with surgery alone. Once it grows deeper than 4 mm, the cancer is far more likely to have sent cells to other parts of the body, even if imaging doesn’t show it yet. The jump from under 1 mm to over 4 mm represents a shift from near-certain survival to roughly coin-flip odds over five years.
How Immunotherapy Changed Advanced Melanoma
A decade ago, a diagnosis of metastatic (stage IV) melanoma meant a median survival of less than a year. That picture has changed dramatically. Long-term data from a landmark international trial shows that the median survival for patients treated with a combination of immune checkpoint inhibitors is now a little over six years. About half of those patients survive cancer-free for 10 years or more.
What’s especially encouraging is the durability of these responses. Patients who are still doing well at three to five years after starting treatment are likely to continue doing well long-term. The cancer doesn’t tend to come back late in people who responded strongly to immunotherapy. This suggests that for a meaningful portion of patients, immunotherapy can produce something close to a functional cure, even in stage IV disease.
Not everyone responds to immunotherapy, and side effects can be significant. But the shift from single-digit survival rates to roughly 50% long-term survival represents one of the biggest advances in cancer treatment in the past two decades.
Targeted Therapy for BRAF-Mutant Melanoma
About half of all melanomas carry a specific genetic mutation that drives the cancer’s growth. Drugs that block this pathway can shrink tumors in roughly 50% of patients who have the mutation, often within weeks. In clinical trials, patients treated with these targeted drugs had overall survival rates of 57% to 84% at one year, compared to 22% to 64% for older chemotherapy.
The challenge is that tumors typically develop resistance after about five to seven months on targeted therapy alone. Combining two types of targeted drugs extends that timeline. In patients who hadn’t received prior treatment, the median overall survival with combination targeted therapy reached nearly 32 months, and the survival rate plateaued around 39% at four years.
Today, targeted therapy is often used alongside or after immunotherapy. Your oncologist will test your tumor for this mutation, and its presence or absence shapes the entire treatment strategy.
Recurrence Risk Over Time
Even after successful treatment, melanoma can come back. The risk of recurrence varies sharply by stage at original diagnosis. Ten-year recurrence-free survival rates give a clearer picture of long-term risk than five-year numbers:
- Stage IA: 88% to 91% still recurrence-free at 10 years
- Stage IB: 79% to 80%
- Stage IIA: 62% to 64%
- Stage IIB: 56%
- Stage IIC: 33% to 49%
This means that even a stage IIA melanoma, which is localized and has a nearly 100% five-year survival rate, still carries a roughly 36% to 38% chance of coming back within a decade. That’s why follow-up monitoring continues for years after treatment. Most recurrences happen in the first few years, but late recurrences are possible with melanoma in a way they aren’t with many other cancers.
Melanoma Subtype Matters
Not all melanomas behave the same way. Acral lentiginous melanoma, which develops on palms, soles, or under nails, has a 5-year survival rate of about 80% to 81%, compared to 91% to 93% for the more common types of skin melanoma. This gap isn’t because the cancer is inherently more aggressive. It’s largely because acral melanomas are found in locations people don’t check as often, so they tend to be thicker at diagnosis.
Acral lentiginous melanoma is the most common type in people with darker skin tones, who may not think of themselves as being at risk for skin cancer. The survival gap could narrow with earlier detection.
What Shapes Your Individual Outlook
Population survival statistics give you a framework, but your individual prognosis depends on several overlapping factors: the stage at diagnosis, how deep the tumor grew, whether the cancer has ulcerated (broken through the skin surface), your age, and the genetic profile of the tumor. Younger patients and women tend to have somewhat better outcomes at every stage, though the reasons aren’t fully understood.
The most important variable remains timing. A melanoma caught early, when it’s thin and confined to the skin, is one of the most curable cancers. A melanoma caught late is serious but increasingly treatable. The survival landscape for advanced melanoma has shifted so dramatically in the past decade that statistics from even five years ago understate what’s possible with current treatments.